Journals / İzmir Göğüs Hastanesi Dergisi / 2015 / Cilt: 29 - Sayı: 3

PROGNOSTIC IMPORTANCE OF SUV MAX VALUE IN PET/CT AND CORRELATION SUV MAX VALUE BETWEEN LYMPH NODE, DISTANT METASTASIS IN NON SMALL CELL LUNG CANCER

KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ OLGULARINDA PET/BT'DEKİ PRİMER TÜMÖR SUVMAX DEĞERİNİN PROGNOSTİK DEĞERİ VE UZAK ORGAN, LENF NODU METASTAZI İLE İLİŞKİSİ

Pages
127–137
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was considered that SUVmax does not play an important role in the survival period of NSCLC patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In our study, we aimed to investigate the correlation between the SUVmax value of pre-treatmentFDG-PET/CT and survival and to determine whether the SUVmax value of primary tumor correlates with distant organs or lymph node metastases in non-small cell lung cancer (NSCLC) patients.
📊
Key Findings & Data:Material and Methods: Between January 2010-December 2013 newly diagnosed and scanned withFDG-PET/CT208NSCLCpatientswereanalyzed retrospectively at İzmir Dr.
💡
Conclusion & Impact:Conclusion: It was considered that SUVmax does not play an important role in the survival period of NSCLC patients.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: In our study, we aimed to investigate the correlation between the SUVmax value of pre-treatmentFDG-PET/CT and survival and to determine whether the SUVmax value of primary tumor correlates with distant organs or lymph node metastases in non-small cell lung cancer (NSCLC) patients. Material and Methods: Between January 2010-December 2013 newly diagnosed and scanned withFDG-PET/CT208NSCLCpatientswereanalyzed retrospectively at İzmir Dr. Suat Seren GöğüsHastalıklarıCerrahisiEğitimAraştırma Hastanesi, 2nd chest diseases clinic. From the files of the cases patients's sex,age,smoking history, performance status,date of diagnosis, histological type,stage,first progression date, death date and FDG-PET/CTSUVmaxvaluesoftheprimarytumor,lymph node and metastases were recorded in the SPSS. Survival time was defined as;between thedateofdiagnosisandthedateofdeathsearchedfromMernisSystemorthelastapplication date to us whether patient is alive. Results: TSUVmaxvaluesweresignificantlyhigher in men and tumor size greater than 5 cm(p:0,025andp:0,001).TSUVmaxvaluewassignificantlylowerinAdenocarcinoma(p:0,01).There was no statistically significant difference between T SUVmax value and the stage and tumor localization (p:0,0530, p:0,0902) TSUVmax value were found statistically significantly lower in T1 patients (p =0.011) than in T4 patients (p=0.019). There was no statistically significant difference between N and M factor and T SUVmax values (p> 0.05).TSUVmaxvaluewas15,03±6,07and15.33±6.50 in alive, death patients respectively. There was no difference between T SUVmax value and alive, death patients (p=0.74). Conclusion: It was considered that SUVmax does not play an important role in the survival period of NSCLC patients.

Özet

Amaç: Çalışmamızda Küçük hücreli dışı akciğer kanserli (KHDAK) olgularda, tedavi öncesi Floro deoksiglikoz-PozitronEmisyonTomografiveBilgisayarlıTomografi'de(FDG-PET/BT)SUVmax(standartuptakevalue)değerinin;sağkalımilekorele olup olmadığını belirlemek ve primer tümör SUVmax değerinin uzak organ ya da lenf bezi metastazı ile ilişkisini araştırmayı amaçladık. Yöntem ve Gereç: Ocak 2010-Aralık 2013 tarihleri arasında İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim Araştırma Hastanesi 2. serviste yeni tanı konulan ve evrelemesinde FDG-PET/BT kullanılan 208 KHDAK'li olgunun dosyaları retros-pektifolarakincelendi.Olgularındosyalarından hastaların cinsiyet, yaş, sigara öyküsü, performans durumu,tanıtarihi,histolojiktipi,evresi,ilkprogresyon tarihi, ölüm tarihi ve kitle, lenf nodu ve metastaz gelişmiş odağın FDG-PET/BT'deki SUVmax değerleri SPSS programına kaydedildi. Bulgular: T SUVmax ortalama değeri erkeklerde ve tümörçapı5cmüzerindeolanlardaanlaml derecede yüksek bulundu (sırasıylap:0,025vep:0,001). Tümör tipi adenokanser olanlarda T SUVmax değeri anlamlı düzeyde düşük saptandı (p:0,01).T SUVmax değeri ile evre ve tümörün yerleşim yeri olan periferik ya da santral olması arasında istatis-tikselolarakanlamlıfarksaptanmadı(sırasıyla p:0,0530, p: 0,0902).T SUVmax ortalaması T1 olan-larda istatistiksel olarak anlamlı düzeyde düşük (p:0,011)saptanırken, T4 olanlarda ise istatistiksel olarak anlamlı düzeyde yüksek bulundu (p:0,019). N ve M faktörü ile T SUVmax değeri arasında istatistikselolarakanlamlıfarksaptanmadı(p>0,05).PrimertümörTSUVmaxdeğeri,sağkalan hastalarda 15,03±6,07 iken ölen hastalarda ise 15,33±6,50 idi. Sağ kalan ve ölen hastalar ile primer tümör T SUVmax ortalama değeri arasında istatistikselolarakanlamlıfarksaptanmadı(p:0,74) Sonuç: Bu çalışma, KHDAK'lı olguların, sağkalım süresinde FDG-PET/BT'deki primer tümör SUVmax değerinin önemli rolü olmadığını düşündürtmüştür.

🔖

Cite This Article

GÜLDAVAL, F., YAVUZ, M. Y., YALÇINKAYA, E., DERYA, K., ANAR, C. M., ÜNSAL, İ., HALİLÇOLAR, H. (2022). PROGNOSTIC IMPORTANCE OF SUV MAX VALUE IN PET/CT AND CORRELATION SUV MAX VALUE BETWEEN LYMPH NODE, DISTANT METASTASIS IN NON SMALL CELL LUNG CANCER. İzmir Göğüs Hastanesi Dergisi, Cilt: 29 - Sayı: 3, 127–137. https://ajindex.com/articles/652200

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Shields TW. Surgical Treatment of nonsmall cell lung cancer. General Thoracic Surgery. Lippincott, Williams and Wilkins 2000:1311-41.
  2. Gail Darling, Carolyn M. Dresler. Clinical Presentation of Lung Cancer in Thoracic Surgery. Churchill Livingstone Inc. ed. F.G.Pearson; 96:1269-1271.
  3. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests and paraneoplastic syndromes. Chest 2003;123: 97-104.
  4. Brundage MD, Davies D. Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest;122:1037-57.
  5. Bury T, Dowlati A, Paulus P. Whole-body FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997:10; 2529-34.
  6. Brink I, Reinhardt J, Hoegerle S, Altehoefer C, Ernst Moser, Egbert U. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: Age dependency and frequency after chemotherapy. J Nucl Med 200;42: 591-5.
  7. Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lungcancer. Am J Roentgenol 2000; 174: 74. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, SchafersHJ. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J NuclMed Mol Imaging 2006;:13-21.
  8. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, HawesSE. Fluorodeoxy glucose uptake of primary non-smallcell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007; 13: 3255-63.
  9. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, andsurvival. J Thorac Cardio vasc Surg 2005; 130: 151-9.
  10. Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18 fluorodeoxy glucose positron emission tomographic maximalstandardized uptake value predicts survival independen tof clinical but not pathologic TNM staging of resected nonsmallcell lung cancer. J Thorac Cardiovasc Surg 2007; 133:1419-, doi: 10.1016/j.jtcvs.2007.01.041 Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roengenol 2000; 174: 1005-8.
  11. Chen JC, Huang TW, Cheng YL, Chang H, Tzao C, Huang WS, et al. Prognostic value of 18-FDG uptake in early stage NSCLC. Thorac Cardiovasc Surg 2009; 57: 413-, d